




>>Entry Name: 9-Aminocamptothecin

Synonym(s): 10-Amino-4-ethyl-4-hydroxy-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-3,14(4*H*,12*H*)-dione, 9Cl. NSC 603071



Molecular Formula: C₂₀H₁₇N₃O₄

Molecular Weight: 363.372

Accurate Mass: 363.121907

Percentage Composition: C 66.11%; H 4.72%; N 11.56%; O 17.61%

Biological Use/Importance: Topoisomerase I inhibitor. Antineoplastic agent

Other Data: Relat. to Camptothecin [CFK58-X](#)

>>Variant: (*R*)-form

CAS Registry Number: 151593-95-2

Molecular Formula: C₂₀H₁₇N₃O₄

Molecular Weight: 363.372

Accurate Mass: 363.121907

Percentage Composition: C 66.11%; H 4.72%; N 11.56%; O 17.61%

Physical Description: Yellow solid

Optical Rotation: [α]_D²²+12 (c, 0.26 in DMF)

>>Variant: (*S*)-form

CAS Registry Number: 91421-43-1

Molecular Formula: C₂₀H₁₇N₃O₄

Molecular Weight: 363.372

Accurate Mass: 363.121907

Percentage Composition: C 66.11%; H 4.72%; N 11.56%; O 17.61%

Physical Description: Orange-yellow amorph. powder (MeOH/CHCl₃)

Melting Point: Mp 300° (dec.)

Optical Rotation: [α]_D²³+16 (c, 0.05 in CHCl₃/MeOH). [α]_D²¹-13 (c, 0.29 in DMF)

Other Data: Pharmacol. active isomer

>>Variant: ($\pm$)-form

Synonym(s): NSC 629971

CAS Registry Number: 130194-90-0

Molecular Formula: C₂₀H₁₇N₃O₄

Molecular Weight: 363.372

Accurate Mass: 363.121907

Percentage Composition: C 66.11%; H 4.72%; N 11.56%; O 17.61%

Physical Description: Tan-orange solid (MeOH/CHCl₃)

UV: [neutral] $\lambda_{\max}$ 238 (ϵ 6100); 256 (ϵ 3800) (MeOH) (Berdy)

References:

- Japan. Pat., 1984, Yakult Honsha, 59 51 289; *CA*, **101**, 91319d, (*synth*)
Wani, M.C. *et al.*, *J. Med. Chem.*, 1986, **29**, 2358-2363; 1993, **36**, 2689-2700, (*synth, pmr, ir, pharmacol*)
Hinz, H.R. *et al.*, *Cancer Res.*, 1994, **54**, 3096-3100, (*pharmacokinet*)
Takimoto, C.H. *et al.*, *J. Chromatogr., B: Biomed. Appl.*, 1994, **655**, 97-104, (*hplc*)
Rubin, E. *et al.*, *Clin. Cancer Res.*, 1995, **1**, 269-276, (*clin trial, pharmacokinet*)
Cabri, W. *et al.*, *Tet. Lett.*, 1995, **36**, 9197-9200, (*synth*)
Potmesil, M. *et al.*, *Ann. N.Y. Acad. Sci.*, 1996, **803**, 231-246; 247-255, (*rev, pharmacol, clin trial*)
Robinson, C. *et al.*, *Drugs of the Future*, 1996, **21**, 881-889, (*rev, synth, pharmacol, tox*)
Dahut, W. *et al.*, *J. Clin. Oncol.*, 1996, **14**, 1236-1244, (*clin trial, pharmacol*)
Erickson-Miller, C.L. *et al.*, *Cancer Chemother. Pharmacol.*, 1997, **39**, 467-472, (*pharmacol*)
Loos, W.J. *et al.*, *J. Chromatogr., B: Biomed. Appl.*, 1997, **694**, 435-441, (*hplc*)
Mani, S. *et al.*, *Cancer Chemother.*, 1998, **42**, 84-87, (*clin trial*)